Trevi Therapeutics (TRVI) Other Accumulated Expenses (2018 - 2026)

Trevi Therapeutics' Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $124000.0 for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 44.19% year-over-year to $124000.0 in Q1 2026; TTM through Mar 2026 was $124000.0, a 44.19% increase from a year earlier, with the FY2025 full-year figure at $184000.0, up 327.91% from the prior year.
• Other Accumulated Expenses slipped to $124000.0 in Q1 2026 per TRVI's latest filing, from $184000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $498000.0 in Q4 2022 and bottomed at $6000.0 in Q4 2023.
• The 5-year median for Other Accumulated Expenses is $77000.0 (2022), against an average of $154882.4.
• Across the five-year window, Other Accumulated Expenses slumped 98.8% in 2023 and soared 616.67% in 2024, its largest moves.
• Year by year, Other Accumulated Expenses stood at $498000.0 in 2022, then slumped by 98.8% to $6000.0 in 2023, then surged by 616.67% to $43000.0 in 2024, then surged by 327.91% to $184000.0 in 2025, then tumbled by 32.61% to $124000.0 in 2026.
• Per Business Quant, the three latest TRVI Other Accumulated Expenses figures stand at $124000.0 (Q1 2026), $184000.0 (Q4 2025), and $126000.0 (Q3 2025).